Conduit Pharmaceuticals announced a virtual special meeting of stockholders scheduled for January 9, 2025, at 10:00 a.m. Eastern Time. The meeting will address several key proposals, including the approval of issuing up to 2,862,596 shares upon warrant exercise, 75,000,000 shares upon conversion of a Senior Secured Promissory Note with Nirland Limited, and 58,000,000 shares upon conversion of a Convertible Note with A.G.P./Alliance Global Partners.Additionally, stockholders will vote on amending the company's Certificate of Incorporation to increase authorized shares from 251,000,000 to 601,000,000. Only holders of record as of December 4, 2024, are entitled to vote. The meeting will be conducted entirely online, and stockholders are encouraged to vote in advance.The Board of Directors recommends voting in favor of all proposals. The outcomes of these approvals are crucial for the company's capital structure and future financing activities.

Conduit Pharmaceuticals announced a virtual special meeting of stockholders scheduled for January 9, 2025, at 10:00 a.m. Eastern Time. The meeting will address several key proposals, including the approval of issuing up to 2,862,596 shares upon warrant exercise, 75,000,000 shares upon conversion of a Senior Secured Promissory Note with Nirland Limited, and 58,000,000 shares upon conversion of a Convertible Note with A.G.P./Alliance Global Partners.Additionally, stockholders will vote on amending the company's Certificate of Incorporation to increase authorized shares from 251,000,000 to 601,000,000. Only holders of record as of December 4, 2024, are entitled to vote. The meeting will be conducted entirely online, and stockholders are encouraged to vote in advance.The Board of Directors recommends voting in favor of all proposals. The outcomes of these approvals are crucial for the company's capital structure and future financing activities.